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Abstract
Objective: This study aims to investigate in vitro the effect of the VDR agonist BXL-01-0029 onto IFNc/TNFa-induced
CXCL10 secretion by human skeletal muscle cells compared to elocalcitol (VDR agonist), methylprednisolone, methotrexate,
cyclosporin A, infliximab and leflunomide; to assess in vivo circulating CXCL10 level in subjects at time of diagnosis with IMs,
before therapy, together with TNFa, IFNc, IL-8, IL-6, MCP-1, MIP-1b and IL-10, vs. healthy subjects.
Methods: Human fetal skeletal muscle cells were used for in vitro studies; ELISA and Bio-Plex were used to measure cell
supernatant and IC50 determination or serum cytokines; Western blot and Bio-Plex were for cell signaling analysis.
Results: BXL-01-0029 decreased with the highest potency IFNc/TNFa-induced CXCL10 protein secretion and targeted cell
signaling downstream of TNFa in human skeletal muscle cells; CXCL10 level was the highest in sera of subjects diagnosed
with IMs before therapy and the only one significantly different vs. healthy controls.
Conclusions: Our in vitro and in vivo data, while confirm the relevance of CXCL10 in IMs, suggested BXL-01-0029 as a novel
pharmacological tool for IM treatment, hypothetically to be used in combination with the current immunosuppressants to
minimize side effects.
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Introduction
The idiopathic inflammatory myopathies (IMs) cover a hetero-
geneous group of systemic autoimmune diseases which share
chronic inflammation and infiltration by inflammatory cells in
skeletal muscles, despite the distinct immune effector mechanisms
underlying the specific disease subtypes - mainly dermatomyositis,
polymyositis, inclusion body myositis, necrotizing autoimmune
myositis or myositis associated with systemic disorders. Macro-
phages, dendritic cells (DCs) and T cells with T helper (Th) 1
immune reaction predominance are, indeed, prominently present
in muscles of the different IM types [1,2].
Local accumulation of T cells and macrophages likely
contribute to the deposition of immune complexes within skeletal
muscles [3,4] by releasing functional molecules, such as cytokines
and chemokines.
Nowadays, the concept that skeletal muscle cells behave as
immunoactive counterpart dialoguing with immune system during
inflammation has been widely accepted. Muscle cells actively
participate to inflammation by promoting cytokine-mediated T
cell invasion [5–7]. Among the wide range of proinflammatory
cytokines highly involved in IMs [1,5], interferon (IFN)c and
tumor necrosis factor (TNF)a, both with strong Th1 association,
have been documented to be upregulated in muscle tissue and in
serum of IM patients [5–8]. The IFNc inducible 10 kDa protein,
CXCL10/IP-10, a powerful chemokine known to initiate and
amplify Th1 cell infiltration in several tissue/cell types during
inflammation [9–13], seems to play a pivotal role in muscles of
subjects with IMs during the early inflammatory signals, as well
[1,14–16]. At the onset of several Th1-mediated (auto)immune
diseases, CXCL10 can alter the Th1/Th2 balance [14], driving
early T cell response towards Th1 type immune polarization and
dominance. Tissue/cell accumulation of CXCL10 is thought to
trigger/perpetuate a self-promoting inflammatory loop throughout
the interaction with its specific receptor CXCR3 on Th1 cells
[13,17]. We’have recently reported that human skeletal muscle
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cells (Hfsmc), an in vitro cell system fully chararcterized and
optimized, secreted CXCL10 when challenged by inflammatory
stimuli, likely throughout a TNFa-driven mechanism [10].
Current therapies for IMs, such as corticosteroids and second-
line immunosuppressants - aimed to reduce the side effects of
corticosteroid - are designed to target immune cells. The
observation that nearly 25% of the patients do not respond to
those drugs and are left with disability has been driving the
attention onto the need for new pharmacological tool(s), hopefully
targeting also the muscular component [18]. Some current
immunosuppressants, such as methylprednisolone (MeP), metho-
trexate (MTX), cyclosporin A (CsA) and infliximab have been
shown to exert a little effect onto CXCL10 secretion by human
skeletal muscle cells (Hfsmc) [10].
Vitamin D receptor (VDR) agonists have emerged to exert
pleiotropic activities in (auto)immune regulation [19]. Remark-
ably, they attenuated Th1-mediated inflammation during either
auto- or alloresponse by targeting both immune and resident cells
[9,20,21], thus becoming suitable candidates as novel immuno-
suppressants in autoimmune diseases and transplantation [22,23].
In particular, we have previously shown that two VDR agonists,
BXL-01-0029 and elocalcitol, both retaining vitamin D biologic
activity - with less or without hypercalcemic side effects,
respectively - significantly counteracted CXCL10 secretion by
human thyrocytes, cardiomyocytes and renal tubular cells
[9,20,21]. In particular, BXL-01-0029, a prodrug of BXL-2198
(also known as BXL-219 and Ro 26–2198), has been shown to be
active onto Th1-mediated inflammatory processes in animal
models of autoimmune type 1 diabetes [24] and colonic
carcinogenesis [25]; elocalcitol, proposed for benign prostate
hyperplasia treatment, retains anti-inflammatory properties as
documented in experimental model of autoimmune prostatitis
[26,27].
Herein, we aimed to investigate whether and how BXL-01-
0029, in comparison with elocalcitol, MeP, MTX, CsA, infliximab
and leflunomide (LEF) [28,29], exert any effect onto IFNc- and
TNFa-induced CXCL10 protein secretion by Hfsmc.
Furthermore, we aimed to assess CXCL10 level in serum of
subjects at the time of diagnosis with different subtypes of IMs and
before therapy initiation, together with other cytokines, such as
TNFa, IFNc, interleukin (IL)-8, IL-6, monocyte chemoattractant
protein-1 (MCP-1), macrophage inflammatory protein 1 (MIP-1)b,
categorized as Th1 type and all involved in muscular inflammation
[30,31], and IL-10, classified as Th2 type; sex- and age-matched
healthy subjects were used as controls.
Materials and Methods
Chemicals
DMEM/Ham’s F-12 medium (1:1) with and without phenol
red, phosphate buffered saline (PBS) Ca2+/Mg2+-free, bovine
serum albumin (BSA) fraction V, glutamine, antibiotics, collage-
nase type IV, NaOH, Bradford reagent, 49,6-Diamidino-2-
phenylindole (DAPI), all reagents for western blot, signal
transducer and activator of transcription-1 (Stat-1) inhibitor
fludarabine, phosphatidylinositol 3-kinase (PI3K) inhibitor
LY294002, p38 mitogen-activated protein kinase (MAPK) inhib-
itor SB 203580, extracellular signal-regulated kinase (ERK)
inhibitor U0126, C-Jun NH2-terminal kinase (JNK) inhibitor
(SP600125), MeP, CsA, MTX and LEF were from Sigma Aldrich
(St. Louis, MO, USA). Fetal calf serum was from HyClone (Logan,
UT). 2-mercaptoethanol were from Life Technologies, Inc.
Laboratories (Grand Island, NY). INFc, TNFa, IL-12, IL-18,
IL-2, IL-4 and ELISA kits for human CXCL10 were from R&D
Systems, Inc. (Minneapolis, MN, USA).
BXL-01-0029 and elocalcitol were from Bioxell (Milan, Italy).
Nuclear factor-kB (NF-kB) inhibitor BAY 11–7082 was from Vinci
Biochem S.r.l. (Vinci, Italy). Chimeric monoclonal antibody
infliximab (Remicade) was from Centocor B.V. (Leiden, The
Netherlands).
Antibodies (Abs) for western blot and immunocytochemical
analysis: rabbit polyclonal primary anti-phospho Tyr701 Stat-1 (p-
Stat-1), mouse monoclonal primary anti-phospho Ser536 Nuclear
factor-kB (p-NF-kB), rabbit polyclonal primary anti-Stat-1 were
from Cell Signaling (Danvers, MA, USA); rabbit polyclonal
primary anti-phospho Thr183/Tyr185 JNK (p-JNK), rabbit
polyclonal primary anti-JNK/SAPK1, peroxidase secondary
Abs, all reagents for SDS-PAGE were from Millipore (Billerica,
MA, USA); mouse monoclonal primary anti-b actin, rabbit
polyclonal anti-human primary anti-NF-kB p65 (C-20) were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA); mouse
monoclonal anti-human leucocyte antigen (HLA) class I, Cy3-
labelled secondary antibody were from Sigma Aldrich (St. Louis,
MO, USA); mouse monoclonal anti-HLA class II-FITC conju-
gated was from BD Biosciences (San Jose, California, USA). Plastic
ware for cell cultures and disposable filtration units for growth
media preparation were purchased from Corning (Milan, Italy).
Cell Cultures
Cells were obtained as previously described [10]. Hfsmc were
isolated from 11 fetal skeletal male muscles (four upper and seven
lower limbs) obtained after voluntary abortion (10–12 weeks of
gestation). Legal abortions were performed in authorized hospitals
and written consent was given by the patients for their human fetal
tissue to be stored and used for research. The use of human fetal
tissue for research purposes was approved by the Committee for
investigation in humans of the Azienda Ospedaliero-Universitaria
Careggi, Florence, Italy (protocol nu 6783-04). All samples have
been handled in the same way and maintained in ice-cold PBS
until processed for culture preparation as described elsewhere
[10]. Hfsmc express skeletal muscle specific linage markers, either
proteins and genes - tropomyosin, myosin 1b, sarcomeric actin,
myostatin, heavy chain myosin, myogenin, MyoD, Pax 3 and 7 -
and display a high degree of myogenic purity and reproducibility;
they fuse in myotubes under appropriate conditions and sponta-
neously retain the functional competence of phenotypically mature
skeletal muscular cells together with proliferation ability - albeit
with a limited lifespan - therefore representing an unique tool for
basic research [10]. Confluent cell cultures were split into a 1:2–
1:4 ratio using EDTA-trypsin solution (0.2–0.5%), and used from
5th to 12th passage (5p–12p).
Subjects
We studied 20 Caucasian patients (13 females and 7 males).
Approval by the Local Ethics Committee, Azienda Policlinico
Umberto I Rome Italy, accordance with the principles outlines in
the Declaration of Helsinki, was obtained. Written consents were
obtained. The group included: patients with dermatomyositis
(n = 8), polymyositis (n = 7), polymyositis associated with other
connective tissue diseases (n = 3, one with rheumatoid arthritis,
one with systemic sclerosis and one with Sjogren’s syndrome),
inclusion body myositis (n = 2).
The mean age of patients was 56.4 years (range: 38–82).
Caucasian healthy blood donors (n = 20) sex- and age-matched
without any sign of myositis, arthritis, ongoing inflammatory or
autoimmune conditions, were used as controls in accordance with
VDR Agonists as Therapeutic Tool for Myopathies
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Local Ethical Committee approval. Written informed consents
were obtained.
Serum Samples
Sera from patients were obtained from the blood samples at
time of muscular biopsy for IM diagnosis, before pharmacological
treatment with immunosuppressants; control sera were obtained
from blood of healthy anonymous donors. All blood samples were
collected from peripheral vein and serum was obtained by
centrifugation (3000 rpm for 10 min at 4uC); aliquots were stored
at 280uC until analyzed.
Cytokine Secretion Assays
For CXCL10 secretion assays, 4000 cells/well were seeded in
96-well flat bottom plates and maintained in serum deprivation as
previously described [10]. Thereafter, different stimuli were added
in serum-free medium with 0.1% BSA, according to the
experimental protocols; cells in serum-free medium containing
0.1% BSA and vehicle were used as control.
For dose-response experiments cells were stimulated for 24 h
with IFNc (1000 U/ml)+TNFa (10 ng/ml), with or without BXL-
01-0029 and elocalcitol (10211 or 10210–1026 M), MTX (161027,
261027, 461027, 861027, 1.661026 M), CsA (461028, 861028,
261027, 461027, 861027 M), MeP (1.361027, 361027,
761027,161026, 361026 M), infliximab (361029, 761029,
261028, 361028, 761028, 261027 M) or LEF (961026,
261025, 461025, 961025, 1.861024, 3.761024 M). The drug
concentrations were selected on the basis of their near-therapeutic
doses, according to their pharmacokinetics (Cmax and area under
the time concentration curves, AUC). Supernatants were harvest-
ed and kept frozen at 220uC until performing ELISA assays.
For experiments with cytokine combination Hfsmc were
incubated for 24 h with IFNc (1000 U/ml) or TNFa (10 ng/
ml), alone or combined; either IFNc (1000 U/ml) or TNFa
(10 ng/ml) were combined with IL-12 (50 ng/ml), IL-18 (50 ng/
ml), IL-2 (25 U/ml) and IL-4 (20 ng/ml). The doses for cytokine
combination have been previously optimized and selected on the
basis of the maximal evoked synergistic response, in terms of
CXCL10 protein secretion [10].
For experiments with inhibitors of intracellular pathways cells
were incubated for 24 h with a combination of IFNc (1000 U/
ml)+TNFa (10 ng/ml) with or without 1 h pre-treatment with
fludarabine (50 mM), LY294002 (15 mM), SB 203580 (5 mM),
U0126 (20 mM), BAY 11–7082 (20 mM), SP600125 (100 mM).
Experiments were performed at least five time in triplicate with
different cell preparations.
ELISA
CXCL10 levels were measured in cell culture supernatants
using commercially available kits, according to manufacturer’s
recommendations. The sensitivity and the intra- and inter assay
coefficients of variation were indicated in manufacturer’s instruc-
tions. Quality control pools of low, normal, or high concentrations
for all parameters were included in each assay. The amount of
CXCL10 was expressed as pg/mg of total protein amount or as
percent of IFNc-, TNFa- or IFNc+TNFa-induced secretion, as
appropriate. Protein extraction and measurement to normalize
Hfsmc secretion were performed as reported elsewhere [11].
Experiments were performed at least in triplicate with at least five
different cell preparations.
Immunoblot Analysis
For protein analysis, Hfsmc, seeded and maintained in the same
conditions as previously reported [10], were stimulated with TNFa
(10 ng/ml) or IFNc (1000 U/ml) for 12 minutes in presence or
absence of BXL-01-0029 (1028 M) in serum-free medium
containing 0.1% BSA. Cells in serum-free medium with 0.1%
BSA and vehicle were used as control. Protein concentration
measurement was performed with Bradford Reagent.
Protein aliquots (20 mg) were processed, loaded onto 10% SDS-
PAGE and transferred on PVDF membranes, according to the
procedure previously described [10]. Thereafter, membranes were
incubated with primary Abs appropriately diluted in Tween Tris-
buffered saline (TTBS) (for anti-p-Stat-1, anti-Stat-1, anti-p-JNK,
anti-JNK, anti-p-NF-kB, anti-NF-kB 1:1000; for anti-b actin
1:10000), followed by peroxidase-conjugated secondary IgG
(1:10000). Proteins were revealed by the enhanced chemilumines-
cence system (ECL plus; Millipore). Image acquisition were
performed with Image Quant Las 4000 software (GE Healthcare)
and densitometric analysis with Quantity OneH software (Bio-Rad
laboratories Inc.). Western blot analysis was performed for three/
four independent experiments with different cell preparations.
Bio-Plex Phosphoprotein Assay
After stimulation, Hfsmc were washed with ice-cold PBS,
harvested and lysed in a phosphoprotein-lysis-buffer (Bio-Rad
Laboratories, Inc.). After centrifugation (4500 g, 20 min, 4uC), the
supernatant containing the phosphoprotein was collected and
protein measurement performed.
Phospho-ERK1/2 were measured in triplicates using the Bio-
Plex protein array system (Bio-Rad Laboratories, Inc.), according
to the manufacturer’s protocol.
The system is a multiplexed particle-based flow cytometric assay
that utilizes anti-phosphokinase monoclonal antibodies linked to
microspheres incorporating distinct proportions of two fluorescent
dyes. Experiments were performed in triplicate with different cell
preparations.
Immunocytochemistry
To evaluate class I and II HLA protein expression, 104 cells
were seeded on glass coverslips in growth medium, maintained in
serum-free medium overnight and then treated with TNFa
(10 ng/ml)+IFNc (1000 U/ml) for 24 and 48 hours, with and
without BXL-01-0029 (1028 M), or with VDR agonist alone. Cells
in phenol red- and serum-free medium 0.1% BSA and vehicle
were used as control. Immunostaining procedure was as previously
described [10]; primary Ab against class I HLA was used at 1:5
dilution and was followed by CY3 conjugated mouse secondary
Ab (1:200); FITC-conjugated Ab against class II HLA was used at
1:10 dilution. DAPI nucleic acid stain was used to stain nuclei
(1:10000). Slides lacking the primary Ab or stained with the
corresponding nonimmune serum were processed for method
specificity. Slides were examined with Zeiss Z1 microscope and
Leica TCS SP2 (Leica, Milano, Italy); images were acquired at
100X magnification. For quantification: the percentage of class I
or II HLA positive cells was calculated by counting the number of
stained cells over the total in at least 15 separate field per slides.
Experiments were performed four times with different cell
preparations.
Multiplex Cytokine Assay
Serum levels of CXCL10, TNFa, IFNc, IL-8, IL-6, MCP-
1 MIP-1b, IL-10 were measured using a magnetic bead-based
multiplex assay (Bio-Plex ProTM Human Cytokine, Chemokine,
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and Growth Factor Assay, Bio-Rad Laboratories, Inc.) according
to the manufacturer’s protocol. A broad sensitivity range of
standards (Bio-Rad Laboratories, Inc.), ranging between 1.95 and
95000 pg/ml were used to help enable the quantitation of a
dynamic wide range of cytokine concentrations and provide the
greatest sensitivity. Data acquisition was performed by Bio-Plex
200 SystemTM (Bio-Rad Laboratories, Inc.) which uses Luminex
fluorescent-bead-based technology (Luminex) with a flow-based
dual laser detector with real-time digital signal processing to
facilitate the analysis of up to 100 different families of colour-coded
polystyrene beads and allow multiple measurements of the sample
ensuing in the effective quantification of cytokines. Data analysis
was performed by Bio-Plex ManagerTM 6.0 software (Bio-Rad
Laboratories, Inc.). Serum samples were run in triplicate twice.
Statistical Analysis
The statistical analysis was performed using GraphPad Prism 5
software (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS
12.0 software package (SPSS for Windows 12.0, SPSS Inc.,
Chicago, IL, USA). The Kolmogorov-Smirnov test for normal
Figure 1. Effect of different immunosuppressors on cytokine-induced CXCL10 secretion in Hfsmc. A, BXL-01-0029 (open triangles),
elocalcitol (closed triangles), MTX (open squares), CsA (closed circles) and MeP (open circles) dose-dependently inhibited IFNc+TNFa-induced CXCL10
secretion (closed squares, taken as 100%, ) after 24 h. Simultaneous fitting of the curves showed that BXL-01-0029 and elocalcitol retained the highest
potency, as shown by the IC50s depicted in the inset of the figure. B, Neither infliximab (closed losangues, left) nor LEF (open losangues, right) exerted
a dose-dependent inhibition of cytokine-induced CXCL10 secretion (closed squares, taken as 100%); IC50 s are reported in figure insets. C, At
concentrations corresponding to the near therapy doses the inhibition by BXL-01-0029, not by elocalcitol, was significantly higher than MeP-, CsA-
and MTX-induced ones (*P,0.05 or **P,0.01 vs. IFNc+TNFa-induced secretion, #P,0.05 vs. all treatment except for elocacitol, uuP,0.01 vs. all other
drugs). Results (mean6S.E.) are expressed as % of IFNc+TNFa-induced CXCL10 secretion (taken as 100%) or % of inhibition. Data are obtained from
five experiments with different cell preparations.
doi:10.1371/journal.pone.0077745.g001
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distribution of the data, one-way analysis of variance (ANOVA),
T-test were applied.
A P value less than 0.05 was considered significant and
corrected for comparison using the Dunnett’s or Bonferroni’s post
hoc test, where appropriate. The computer program ALLFIT
(NIH, Bethesda, MD, USA) [32] was used for analyses of sigmoid
dose-response curves to obtain estimates of IC50s of BXL-01-0029,
elocalcitol, MTX, CsA, MeP, infliximab and LEF. Data are
expressed as mean6S.E.
Results
BXL-01-0029 Inhibited CXCL10 Secretion by Hfsmc with
the Highest Potency
Drug pharmacologic potency was determined in Hfsmc
incubated with IFNc (1000 U/ml)+TNFa (10 ng/ml) and in-
creasing concentrations of BXL-01-0029, elocalcitol (10211 or
10210–1026 M), MTX (161027, 261027, 461027, 861027,
1.661026 M), CsA (461028, 861028, 261027, 461027,
861027 M), MeP (1.361027, 361027, 761027, 161026,
361026 M), infliximab (361029, 761029, 261028, 361028,
761028, 261027 M) and LEF (961026, 261025, 461025,
961025, 1.861024, 3.761024 M).
As revealed by dose-response curves (Figure 1A and 1B), all
drugs significantly reduced IFNc+TNFa-induced CXCL10 re-
lease by Hfsmc (P,0.05 or P,0.01 vs. IFNc+TNFa-induced
secretion, taken as 100%, starting from the first or the second
lowest drug concentrations, Figure 1A: BXL-01-0029, elocalcitol,
MTX, CsA, MeP; Figure 1B: infliximab and LEF). CXCL10
secretion was virtually absent in control cells (not shown).
In particular, infliximab and LEF (Figure 1B, left and right,
respectively) did not display a dose-dependent effect similar to the
other tested drugs; instead, they both appeared to be toxic onto
Hfsmc (not shown). The cytotoxic effect may explain, at least in
part, the highest maximal inhibition of infliximab and LEF onto
CXCL10 secretion observed at fixed concentrations correspond-
ing to the related near therapy doses (Figure 1C, P,0.01 vs.
control and vs. all other drugs). The inhibition by BXL-01-0029 at
the near therapy dose (39.7965.16%) - differently from elocalcitol
(30.3367.08%) - was significantly higher (P,0.05) than that one
observed with MeP (19.1063.75%), CsA (21.2663.91%) and
MTX (30.4663.51%).
However, both VDR agonists were the most potent as
compared to the other drugs, as shown by the calculated IC50,
that are: MeP: 2log IC50 = 6.6760.15; MTX: 2log
IC50 = 7.0260.71; CsA: 2log IC50 = 7.4260.26; BXL-01-0029
and elocalcitol: 2log IC50 = 10.6460.42 and 2log
IC50 = 11.0061.68, respectively (inset of Figure 1A); infliximab
2log IC50 = 8.7860.29 and LEF: 2log IC50 = 2.8461.41, (inset
of Figure 1B, left and right). In table 1 the P values for each IC50
vs. the other ones are also reported; BXL-01-0029 displayed an
IC50 value statistically significant vs. all the other tested drugs, but
elocalcitol.
CXCL10 Secretion by Hfsmc was Specifically Induced by
TNFa and IFNc Synergy and Impaired by the Inhibition of
TNFa-related Intracellular Pathways
To verify the specificity of synergy between IFNc and TNFa
onto CXCL10 protein secretion in Hfsmc, we incubated the cells
with IFNc (1000 U/ml) or TNFa (10 ng/ml) alone or combined;
either IFNc or TNFa were combined with IL-12 (50 ng/ml), IL-
18 (50 ng/ml), IL-2 (25 U/ml) and IL-4 (20 ng/ml). The effect of
each single cytokine was tested.
Only IFNc and TNFa combination (Figure 2A) elicited the
highest CXCL10 secretion (2207.846239.80 pg/mg proteins,
P,0.01 vs. control and vs. each other cytokine alone or
combined). With the exception of IFNc and TNFa
(122.37636.73 and 90.07623.16 pg/mg proteins, respectively,
P,0.01 vs. control), none of the single tested cytokine induced
CXCL10 secretion by Hfsmc. TNFa-induced CXCL10 secretion
was enhanced by IL-18 (214.96632.90 pg/mg proteins, P,0.05
vs. TNFa-treated cells).
We next investigated the intracellular pathways involved in
CXCL10 protein secretion induced by IFNc+TNFa in Hfsmc.
Cells were incubated in presence of IFNc (1000 U/ml)+TNFa
(10 ng/ml) with and without the selective inhibitors of Stat-1
(fludarabine), PI3K (LY294002), p38 MAPK (SB 203580),
ERK1/2 (U0126), NF-kB (BAY 11–7082), and JNK (SP600125).
All the inhibitors, with the exception of LY294002 and SB
203580, reduced cytokine-induced CXCL10 secretion (P,0.05 vs.
IFNc+TNFa-induced secretion, taken as 100%) (Figure 2B). In
particular, CXCL10 secretion was mostly reduced by JNK and
NF-kB blockage (more than 80% and 60%, respectively; JNK
inhibition: P,0.05 vs. all other treatments except for BAY 11–
7082; NF-kB inhibition: P,0.05 vs. SB 203580).
BXL-01-0029 Inhibited Signal Pathways Downstream of
TNFa and TNFa-induced CXCL10 Secretion in Hfsmc
We next found that BXL-01-0029 in Hfsmc was able to impair
TNFa signaling by interfering with JNK, NF-kB and ERK1/2
phosphorylation, as shown by protein analysis with western blot
(Figures 3A, 3B) or Bio-PlexH suspension array system (Figure 3C).
In particular, the treatment of Hfsmc with TNFa significantly
increased the phosphorylation of JNK, NF-kB and ERK1/2 vs.
control (Figures 3A, 3B and 3C, P,0.05); the simultaneous
incubation with BXL-01-0029 significantly reduced TNFa-
induced activation of JNK and virtually prevented NF-kB
phosphorylation (Figures 3A and 3B, upper), as confirmed by
the densitometric analysis (Figures 3A and 3B lower, P,0.05 vs.
TNFa-treatment, taken as 1); VDR agonist alone exerted no
effect. Total JNK and NF-kB were used for loading controls
(Figures 3A and 3B, middle).
BXL-01-0029 induced ERK1/2 phosphorylation similarly to
TNFa (taken as 1, P,0.05 vs. control, Figure 3C) and exerted an
additive effect when combined with TNFa, as revealed by Bio-
Plex analysis (P,0.05 vs. TNFa-treatment). BXL-01-0029 signif-
icantly decreased TNFa-induced CXCL10 protein secretion by
Hfsmc (Figure 3D).
BXL-01-0029 did not Affect Signal Pathway Downstream
of IFNc and IFNc-induced CXCL10 Secretion in Hfsmc
BXL-01-0029 did not exert a significant effect onto Stat-1
phosphorylation induced by IFNc, taken as 1, (Figure 4, upper), as
confirmed by densitometric analysis (Figure 4 lower, P,0.05 vs.
control); total Stat-1 used as loading control is depicted (Figure 4A,
middle). IFNc-induced CXCL10 secretion (taken as 100%,
Figure 4B) was unaffected by BXL-01-0029.
BXL-01-0029 Counteracted Cytokine-induced Class II HLA
Expression in Hfsmc
Class I and class II HLA expression, virtually absent in control
Hfsmc (Figure 5A, left), significantly increased after the treatment
with IFNc (1000 U/ml)+TNFa (10 ng/mL) for 24–48 h: almost
100% increase of class I at both time points; more than 50%
increase of class II HLA, at 24 and 48 h, respectively (Figure 5A,
middle and Figure 5B, 5C). The simultaneous addition of BXL-
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01-0029 (1028 M) did not affect the number of cytokine-induced
class I HLA positive cells, at each time point (Figure 5, right and
Figure 5B). Conversely, after 24–48 h, the VDR agonist signifi-
cantly decreased the number of class II HLA positive cells vs.
cytokine-treated cells (at 24 h: 27.5165.81% with BXL-01-0029
vs. 50.7566.86% with IFNc+TNFa, P,0.05; at 48 h:
23.5463.31% with BXL-01-0029 vs. 54.9662.21% with
IFNc+TNFa, P,0.01; Figure 5, right and Figure 5C). Figures
are representative. No effects were observed in cells treated with
BXL-01-0029 alone or processed for method control (not shown).
CXCL10 Serum Level was the Highest in IM Patients at
the Time of Diagnosis
In subjects diagnosed with IMs before therapy initiation
CXCL10 serum level was the highest out of the other measured
cytokines TNFa, IFNc, IL-8, IL-6, MCP-1, MIP-1b (Th1 type)
and IL-10 (Th2 type) (P,0.01, Figure 6), and the only one
significantly different from matched healthy controls (P,0.05).
Discussion
This study highlights for the first time that a VDR agonist
counteracted cytokine-induced CXCL10 secretion by human
skeletal muscle cells throughout TNFa pathway deactivation.
The IC50 values documented that BXL-01-0029 targeted human
skeletal muscle cells by inhibiting TNFa+IFNc-induced CXCL10
secretion with the highest potency as compared to the other tested
immunosuppressants. This effect might be due, at least in part, to
the impairment of NF-kB and JNK intracellular pathways, both
downstream of TNFa [33,34]; remarkably, BXL-01-0029 seems to
prevent NF-kB activation, as shown by the virtual absence of its
phosphorylation in presence of the VDR agonist. This latter
observation is in line with the effect previously reported in human
cardiomyocytes [21]; indeed, NF-kB and TNFa-related pathways
are well known vitamin D targets [35]. Accordingly, CXCL10
secretion induced by TNFa, alone or combined with IFNc, was
significantly decreased by BXL-01-0029. Based on the result
observed on ERK1/2 signaling pathway, also downstream of
TNFa, we could speculate that BXL-01-0029 likely affects VDR
activity in Hfsmc; indeed, it is known that VDR ligands interfere
with ERK signaling by rapid mechanism. While ERK pathway
activation is associated with the significant increases in pro-
inflammatory cytokine transcription [36] during muscle inflam-
mation, the effect of ERK activation on VDR transcriptional
activity (i.e., enhancement or attenuation) is cell specific and
depends on the type of the retinoid X receptor (RXR) engaged as
heterodimer partner, such as a, b and c isoforms, all expressed by
human skeletal muscle [37].
As from our data in Hfsmc, BXL-01-0029 seems to selectively
target TNFa signaling pathway without interference onto IFNc, as
shown by no significant changes either in Stat-1 phosphorylation
or in IFNc-induced CXCL10 secretion. This result is quite
different from the inhibition of IFNc-induced Stat-1 phosphory-
lation and activation previously observed in human thyrocytes and
cardiomyocytes treated with BXL-01-0029 or elocacitol, respec-
tively [20,21]; hence, we could hypothesize a different/specific
effect of VDR agonists depending also on target cell types.
Herein, we documented that the significant CXCL10 protein
secretion by Hfsmc - virtually absent in basal condition – as
observed under inflammatory challenge occurred in association to
NF-kB, JNK or ERK intracellular path activation, whose specific
blockage significantly reduced chemokine secretion; class I and II
HLA expression was consistently increased as well. The latter
effect is in line with data from other groups showing an
upregulation of class I and II HLA both in vivo in IM and in vitro
upon pro-inflammatory cytokine stimulation [38–42]. At variance
with previous studies in human myoblasts, constitutive HLA I was
not detectable in Hfsmc: this may be due to the reduced/different
immunogenicity of fetal cells [43–45]. However, Hfsmc - capable
to respond to an allogenic in vitro stimulation, as previously shown
[10] - have now been documented to be equipped with the major
constituents necessary for antigen processing. In this view, the
compliance of Hfsmc as an optimal in vitro tool for basic research
in human muscle inflammation has been confirmed. Differently
from class I HLA, whose induction by proinflammatory stimuli did
not change with VDR agonist, cytokine-induced class II HLA
expression in Hfsmc seems to be counteracted by BXL-01-0029.
This result is quite intriguing since class II HLA class molecules
lead to the immunogenic presentation of autoantigents to CD4+T
cells [39]. Remarkably, cytokines have been shown to contribute
to pathogenesis of IM by upregulating HLA [46] and TNFa, in
particular, has been recently hypothesized as a key mediator and
potential therapeutic target in T cell mediated IM [42]. The
association between HLA, TNFa polymorphisms and genetic risk
for the pathogenesis of myositis has been reported in subjects with
polimyositis, dematomyosistis or myositis overlapping with other
connective diseases [47]. As from studies in IM patients and
murine cells, TNFa-mediated pathway seems to mediate the
modification of the alternative splicing factor ASF/SF2, which is
known to have a major role in inflammation and autoimmune
Table 1. Comparison of the calculated IC50 s.
P value
BXL-01-0029 elocalcitol infliximab CsA MTX MeP LEF
BXL-01-0029 – ns 0.0026 0.0002 0.0145 0.0070 ,0.0001
elocalcitol Ns – 0.0452 ns 0.0408 0.0122 0.0077
infliximab 0.0026 0.0452 – ns 0.0323 0.0147 ,0.0001
CsA 0.0002 ns ns – ns 0.0067 Ns
MTX 0.0145 0.0408 0.0323 ns – Ns 0.0385
MeP 0.0070 0.0122 0.0147 0.0067 ns – 0.0397
LEF ,0.0001 0.0077 ,0.0001 ns 0.0385 0.0397 –
P values for each IC50 vs. the other ones are depicted in Table 1; only BXL-01-0029 displayed an IC50 value statistically significant vs. all the other tested molecules, but
elocalcitol.
doi:10.1371/journal.pone.0077745.t001
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muscle diseases [48]. TNFa, quite differently from IFNc - rapidly
degraded and, therefore, not always easily detectable - is highly
expressed in tissues and blood of IM patients [5,49] and it seems
the pivotal cytokine in promoting muscular inflammation at
cellular level [50,51]. The importance of TNFa in myositis
development has been recently confirmed and highlighted in an
animal model [52]. Accordingly, we have previously shown that
the system TNFa-TNFa receptor (TNFaR) type II is likely the
critical one in promoting muscular inflammation at cellular level
in Hfsmc, throughout the synergy with IFNc. As documented by
the combination with some other Th1 type cytokines, known to be
engaged in skeletal muscle inflammation, such as IL-12, IL-18, IL-
2 [53,54], or with IL-4 (Th2 type), there is a specific synergistic
effect only in presence of TNFa+IFNc; such a specificity is
associated to a significant up-regulation of TNFa type II receptor
[10], the subtype mainly engaged in immune response regulation,
as we previously reported [55,56].
In clinics, pharmacological blockade of TNFa activity – i.e., by
the neutralizing antibody infliximab or the soluble TNFaR
Etanercept – used to reduce symptoms of rheumatoid arthritis
or Crohn’s disease, has been since few years ago extended also to
IMs, although some caution has been recommended [18,57–59].
A screening for detecting potentially valuable inhibitors of NF-kB,
in order to block TNFa activity and identify non toxic optimal
therapies for the inflammatory myopathies, has been repoted in a
murine cell line [60].
So far, while our study is in keeping with previous in vivo and
in vitro observations, it provides for the first time in vitro evidence
for human skeletal muscle cell contribution to immune/inflam-
matory processes through TNFa pathway, and, more importantly,
it highlights potential target(s) at muscle cell level. In our opinion,
the use of human cellular system is a key point in basic research, in
order to avoid any species-specificity bias.
Our data indirectly confirm and sustain the critical role of
TNFa in human IM pathogenesis, providing new insight(s) at
molecular level: as from previous [10] and present results,
CXCL10 production and its main triggering path, the intracellular
cascade downstream of TNFa, have emerged as potential new
therapeutic targets in muscular inflammation. Muscular cells,
although being not the main source in vivo, can produce CXCL10
during inflammatory conditions, as shown by immunohistochem-
ical studies in skeletal muscle fibers of patients with juvenile
dermatomyositis [15]. CXCL10 not only mediates leukocyte
recruitment and infiltration at the site of inflammation during the
early stages of auto- or alloimmune response, but, and even more
important, likely triggers the reaction following the antigenic
challenge [17]; in this light, we hypothesize that pharmacological
targeting local production of CXCL10 by VDR agonist could be a
novel helpful therapeutic approach to inflammatory disorders of
the muscle. Remarkably, circulating CXCL10 level was the
highest as compared to each other tested Th1 cytokine level in sera
of subjects at time of diagnosis with IMs; furthermore, only
CXCL10 was significantly higher in patients than in matched
controls. However, we’d like to underline some difference in
TNFa serum level between the two groups of subjects, although
not statistically significant, probably due to sample variability. Of
note, some of our in vivo results obtained at the time of diagnosis
are in line with a previous study on some circulating Th1 type
cytokines in subjects with different types of IMs, in active phase of
the diseases [49]. Albeit many of the immunopathogenic processes
behind IMs remain poorly understood, is generally accepted that
cytokines and chemokines, including IFNc, TNFa and CXCL10,
are pivotal players and may be defined as ‘‘disease-perpetuating’’
molecules; correlational clustering is able to discriminate between,
and, hence, sub-classify patients with IMs [1,49]. In addition,
cytokine profile during treatment - before and after MeP, CsA,
MTX or intravenous Ig - permitted to identify some key cytokines
clearly reflecting the disease improvement, thus to be considered
as excellent candidates for therapeutic efficacy indicators [49].
Current therapeutic approaches for IMs target mainly immune
cells, as mentioned above, and are based mostly on empirical
evidence; the absence of internationally validated evaluation
criteria to conduct randomized controlled trials - due both to
low prevalence and heterogeneity of IMs - represents a major
concern in clinics [18]; the inadequate response and the
intolerance to the therapy, often encountered by IM patients,
predict a poor outcome. Thus, new agents designed to target
specific different component(s) to the immune response other than
Figure 2. Evaluation of IFNc+TNFa synergy and intracellular
pathways involved in CXCL10 secretion by Hfsmc. A, CXCL10
secretion, virtually absent in control, was significantly increased by 24 h
treatment with IFNc (1000 U/ml) and TNFa (10 ng/ml) and enhanced at
the highest level only by their combination; *P,0.05 or **P,0.01 vs.
control; uuP,0.01 vs. each other cytokines, single or combined. IL-12
(50 ng/ml), IL-18 (50 ng/ml), IL-2 (25 U/ml) and IL-4 (20 ng/ml) had
effect onto neither IFNc- nor TNFa-induced CXCL10 secretion, except
for IL-18 combined with TNFa (uP,0.05 vs. TNFa-induced secretion).
Data are expressed as pg/mg protein, mean6S.E. Results are obtained
from six experiments with different cell preparations. B, IFNc+TNFa-
induced CXCL10 secretion was significantly reduced by the blockade of
different intracellular pathways with the specific inhibitors: fludarabine
(Stat-1) 66.0866.05%; LY294002 (PI3K) 77.6610.97%; SB 203580 (p38
MAPK) 91.70612.86%; U0126 (ERK1/2) 60.7066.88%; BAY 11–7082 (NF-
kB) 39.40612.71%; SP600125 (JNK) 17.84610.10%. *P,0.05 vs.
IFNc+TNFa-induced secretion, taken as 100%; #P,0.05 vs. all other
treatments except for BAY 11–7082; 1P,0.05 vs. SB 203580. Results
(mean6S.E.) are expressed as % of IFNc+TNFa-induced CXCL10
secretion (taken as 100%). Data are obtained from five experiments
with different cell preparations.
doi:10.1371/journal.pone.0077745.g002
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Figure 3. Effect of BXL-01-0029 onto TNFa-treated Hfsmc. A, B, Western blot analysis was performed to assess JNK (A) and NF-kB (B) activation
after 12 min stimulation with TNFa (10 ng/ml), with or without BXL-01-0029 (1028 M). TNFa induced JNK and NF-kB phosphorylation; BXL-01-0029
impaired JNK activation and prevented NF-kB phosphorylation (upper A and B); total JNK and NF-kB were used as loading control (middle A and B).
Lower A and B report densitometric analysis (*P,0.05 vs. control, #P,0.05 vs. TNFa-treated cells) and results are expressed as ratio phosphorylated/
total protein arbitrary units vs. TNFa-treated cells, taken as 1 (mean6S.E.). C, Bio-Plex protein analysis assessed ERK1/2 activation after 12 min
stimulation with TNFa (10 ng/ml), with or without BXL-01-0029 (1028 M). TNFa and BXL-01-0029 induced ERK1/2 phosphorylation (*P,0.05 vs.
control); their combination enhanced this effect (#P,0.05 vs. TNFa-treated cells). Results are expressed as fold of relative p- to tot-ERK1/2 expression
vs. TNFa-treated cells, taken as 1 (mean6S.E.). Data were obtained from two experiments with different cell preparations. D, TNFa-induced CXCL10
secretion, taken as 100%, was significantly reduced by BXL-01-0029 (1028 M) after 24 h incubation; *P,0.05 vs. TNFa-induced secretion. Results
(mean6S.E.) are derived from five experiments, using distinct cell preparations.
doi:10.1371/journal.pone.0077745.g003
Figure 4. Effect of BXL-01-0029 onto IFNc-treated Hfsmc. A, Western blot analysis to assess Stat-1 activation after 12 min stimulation with
IFNc (1000 U/ml), in presence or absence of BXL-01-0029 (1028 M) showed that IFNc increased Stat-1 phosphorylation, whereas BXL-01-0029 did not
exert any effect (upper A); total Stat-1 was used as loading control (middle A). The densitometric analysis is reported in lower A (*P,0.05 vs. control)
and results are expressed as ratio phosporylated/total protein arbitrary units vs. IFNc-treated cells, taken as 1 (mean6S.E.). B, Cell incubation for 24 h
with BXL-01-0029 (1028 M) did not affect IFNc-induced CXCL10 secretion, taken as 100%. Results (mean6S.E.) are derived from five experiments,
using distinct cell preparations.
doi:10.1371/journal.pone.0077745.g004
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immune cells, such as muscular cells, would be high attractive.
The finding that in human skeletal muscle cells BXL-01-0029 is
the most potent inhibitor of CXCL10 secretion, by specifically
targeting the intracellular signal pathway downstream of TNFa,
might be quite intriguing in view of new potential pharmacological
tool(s) for the treatment of IMs, as above reported. Thus far, based
on the rapid actions as observed onto intracellular path activation,
we could hypothesized a non genomic effect of VDR analogue;
however, alternative mechanism(s) of action, i.e., involving effects
on other intracellular pathway(s) or cytokine receptor(s) cannot be
excluded. It is also noteworthy that both BXL-01-0029 and
elocalcitol have been documented to significantly decrease
CXCL10 secretion by CD4+T cells without any cytotoxic effect
onto cell viability, at variance with some other immunosuppres-
sants [9,21]. We want to remark that we selected drug
concentrations on the basis of their near-therapeutic doses,
according to their pharmacokinetics, in order to reflect the serum
concentrations of drugs administered to patients.
Figure 5. Effect of BXL-01-0029 on IFNc+TNFa-induced class I and class II HLA in Hfsmc. A, Immunocytochemistry revealed no constitutive
expression of class I and class II HLA in control Hfsmc (left A); positive staining for both antigens was observed after 24–48 h incubation with
IFNc+TNFa (middle A); BXL-01-0029 significantly counteracted cytokine-induced class II HLA expression at both time points, with no effect onto class I
HLA (right A). Pictures are representative. B, C, Cells were scored as either positive or negative for class I and class II HLA, respectively. Stained cells for
each antigen were virtually absent in control cells (class I HLA: 2.360.19% and 0.560.3% for class I and II HLA, respectively). Stimulation with
IFNc+TNFa induced virtually all Hfsmc to express class I HLA (98.860.8% at 24 h; 99.160.9 at 48 h, **P,0.01 vs. control) and about half of the cells to
express class II HLA (50.7566.86% at 24 h; 54.9662.21% at 48 h, **P,0.01 vs. control). The simultaneous incubation with BXL-01-0029 significantly
decreased the number of class II HLA-stained cells after 24 h (27.5165.81%, #P,0.05 vs. cytokine-treated cells) and 48 h (23.5463.31%, ##P,0.01 vs.
cytokine-treated cells). Results are obtained with four different cell preparations and expressed as the percentage of positive cells over the total
(mean6S.E.).
doi:10.1371/journal.pone.0077745.g005
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In conclusion, albeit additional studies are mandatory, non or
less hypercalcemic VDR agonists might represent optimal
candidates to be a potentially more effective and safer therapy,
even to combine with the current therapeutic regimens for the
treatment of autoimmune muscular diseases, such as IMs.
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